Successful Completion of Phase 2a Study in Celiac Disease
Start of the phase 2b real-life study of ZED1227 announced
Reversibly acting TG2 inhibitors
Drug candidates for the treatment of fibrosis
Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
Dr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
Press release: Zedira announces ISO 9001:2015 certification
Design of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering